Preparation of SubATVax™ adjuvanted vaccines against inactivated poliovirus, diphtheria toxoid, tetanus toxoid, acellular pertussis, neisseria meningitidis, streptococcus pneumoniae, and haemophilus influenzae polysaccharide conjugates for subcutaneous administration

Title : Preparation of SubATVax™ adjuvanted vaccines against inactivated poliovirus, diphtheria toxoid, tetanus toxoid, acellular pertussis, neisseria meningitidis, streptococcus pneumoniae, and haemophilus influenzae polysaccharide conjugates for subcutaneous administration

Abstract:

In developing nations the cost of commercial vaccines to immunize children against Polio virus, Diphtheria, Tetanus, Pertussis, Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae can be prohibitive. If one could develop inexpensive adjuvants for these approved vaccines, put multiple vaccine antigens in said adjuvant, decrease the volume and number of immunizations, and administer these vaccines subcutaneously, then more children could be immunized at a fraction of the current cost.

During the COVID-19 pandemic, we developed just such an adjuvant system, SubATVax™, for baculovirus expressed proteins which generated systemic levels of IgM, IgG and IgA with a subcutaneous immunization schedule. With our adjuvant system, we have now successfully formulated a Diphtheria toxoid, Tetanus toxoid, and acellular Pertussis vaccine, along with an inactivated Poliovirus vaccine, as well as a multiantigen polysaccharide conjugate vaccine directed against 20 serotypes of Streptococcus pneumoniae, four serotypes of Neisseria meningitidis and Haemophilus influenzae capsular type b. These were encapsulated in a vitamin E containing, nonphospholipid liposome (SubATVax™).

Both adjuvanted vaccines were packaged into 1 mL syringes and a needleless injector technology. Both packaged vaccines were placed on two-year stability studies in 2024. Data on stability testing, to include sizing data, photomicrographs, and real-time videos of the structures, will be presented. In summary, we have developed a new adjuvant system for protein-based vaccines, polysaccharide conjugate vaccines and inactivated whole virus vaccines for potential testing and use in resource-constrained countries.

Audience Take Away Notes:

• We have designed proprietary, patented delivery vehicles for vaccines, called SubATVax™, which can be administered either subcutaneously or intramuscularly.
• The audience will learn how to easily produce our adjuvant system for local use with approved vaccines.
• Our adjuvanted vaccines can be administered subcutaneously through a 25-gauge needle. Adjuvanted vaccines can also be loaded into and administered in needle-free injector systems.

Biography:

Dr. Wright completed an undergraduate degree in Biology from the University of Virginia in 1972, his M.D. degree from the University of Virginia in 1976, an internship in internal medicine at Columbia P&S Harlem Hospital in New York City in 1977. He then spent 3 years in the Army in Germany seeing patients before returning to the United States to complete a two residency in Internal Medicine, a 3 year research fellowship in Infectious Disease both at Walter Reed Army Medical Center in Washington D.C and tropical medicine training at Walter Reed Army Institute of Research. During his fellowship he set-up the first HIV-1 clinic in the military which he continued to run until 1988. He then left to cofound Univax Biologics, the third biotechnology company in Maryland. In 1993 he cofounded Novavax.  Dr. Wight left Novavax in 2006. He has set-up 3 additional companies LPJP, Inc., David Craig Wright, M.D. Inc. (both California S corporations) and D4 Labs, LLC (California LLC). Dr. Wright has authored or co-authored over 20 issued US patents since 1989.